Investing in the critical infrastructure that enables the next generation of therapeutics — from viral vector manufacturing and cold chain networks to AI-driven drug discovery and modular cGMP facilities. The global biotech market hit $2.79 trillion in 2026, but cell and gene therapy production capacity sits at 15–20% of projected 2030 demand. The fund targets the $50–80B infrastructure gap where capital builds the manufacturing backbone of modern medicine.
Setcoin Atlas · live pipeline
Companies and programmes on the public record in the sectors DSE Biotech Lifescience Fund invests in, each placed on the sector’s own gate ladder: from R&D award to contract, raise and production.
By stage (sector gate ladder)
Highlighted rows are in play. Bars on a square-root scale.
By region
Source: Setcoin sector registers — R&D awards, contracts, clearances, raises and facility records. Figures update with each Atlas build. Named projects, sponsors and evidence are available to registered investors in the LP workspace.
Market Context
The global biotechnology market reached $2.79 trillion in 2026, growing at 14% CAGR toward $9 trillion by 2035. But the real investment story is infrastructure: cell and gene therapy production capacity is at 15–20% of projected 2030 demand, cold chain infrastructure fails 15–25% of personalised therapies, and only 3–4 suppliers globally produce the specialised lipids needed for mRNA therapeutics.
~30 approved therapies today, 150–200 projected by 2030. Current production: <50,000 doses/year. Required: 500,000+ doses/year. Viral vector capacity needs 10x scale-up. 18–24 month lead times for new facilities.
100+ mRNA therapeutics in clinical trials for cancer vaccines, personalised immunotherapies, and rare diseases. Lipid nanoparticle production bottleneck: only 3–4 suppliers globally. mRNA therapeutics market projected $50–70B by 2030.
50+ AI drug discovery companies but only 1–2 AI-discovered drugs approved. 2–3x success rate improvement vs traditional. $3–5B specialised compute infrastructure needed. 10^60 possible molecules vs <10^9 currently screened.
mRNA requires -80°C to -20°C storage. Cell therapies need liquid nitrogen (-196°C). 15–25% of personalised therapies fail in last-mile delivery. 500+ regional ultra-cold hubs needed globally. $4–7B investment window.
Dual-Track Model
Whether you're an institutional investor seeking exposure to biotech infrastructure, or a life sciences venture seeking growth capital, we want to hear from you.
We actively seek biotech infrastructure ventures, CDMO platforms, and enabling technology companies addressing critical manufacturing and logistics bottlenecks.
Join leading institutional investors positioning for the biotech infrastructure buildout — targeting the manufacturing, logistics, and computational backbone that every therapeutic developer needs.
Investment Strategy
The DSE Biotech Lifescience Fund targets the critical infrastructure layer where $2.8 trillion in biotech market value meets acute manufacturing constraints. Cell and gene therapy production is at 15–20% of 2030 demand. mRNA lipid nanoparticle supply has only 3–4 global producers. The fund deploys capital into the enabling infrastructure — manufacturing, cold chain, AI compute, and diagnostics platforms — where demand visibility is highest and first-mover advantage creates durable competitive moats with 40–60% gross margins.
Modular cGMP facilities (3–6 month deployment), continuous manufacturing systems, automated cell culture, viral vector and plasmid DNA production, regional manufacturing hubs.
AAV and lentiviral vector manufacturing, CAR-T production platforms, CRISPR delivery systems, automated cell processing, real-time release testing.
Lipid nanoparticle synthesis facilities, in vitro transcription at scale, fill-finish capabilities for ultra-cold products, lyophilisation for room-temperature stability.
Ultra-cold storage networks (-80°C to -196°C), IoT-enabled monitoring with blockchain verification, cryogenic transport systems, distributed point-of-care manufacturing.
Molecular dynamics supercomputers, automated wet-lab facilities (robot scientists), federated learning for clinical data, cloud-based screening platforms.
Next-gen sequencing centres, liquid biopsy infrastructure, AI pathology systems, cryo-electron microscopy, single-cell multi-omics platforms, companion diagnostics.
Geographic Focus:
Critical Infrastructure Gap
The fund thesis is built on deep analysis of the biotech sector's most constrained infrastructure nodes — where demand visibility is highest and supply gaps create outsized return opportunities.
Critical Shortage
Cell and gene therapy production at 15–20% of projected 2030 demand. 18–24 month lead times for new facilities. Viral vector capacity needs 10x scale-up from ~1,000 to 10,000+ litres/year. 500,000+ doses/year needed by 2030.
Acute Constraint
Lipid nanoparticle production — essential for all mRNA therapeutics — has only 3–4 global suppliers. Specialised ionizable lipids and PEG-lipids are the bottleneck for 100+ clinical programmes. 5–7 additional GMP facilities needed immediately.
Infrastructure Gap
mRNA at -80°C, cell therapies at -196°C. 15–25% of personalised therapies fail in last-mile delivery. Inadequate monitoring for temperature excursions. 500+ regional ultra-cold storage hubs needed globally.
Compute Deficit
10^60 possible small molecules vs <10^9 currently screened. Protein structure prediction requires massive compute. 50+ AI drug discovery companies competing for limited specialised GPU/accelerator resources.
Structural Gap
Only 20–30 specialised Advanced Therapy Medicinal Products testing labs globally — need 100+ for projected therapy approvals. Digital quality systems and real-time release testing not widely accepted.
Workforce Crisis
15,000 bioprocess engineer shortage by 2030. Regulatory affairs specialists for ATMPs severely constrained. Computational biologists in demand across pharma, biotech, and AI companies simultaneously.
Infrastructure Investment Priorities
Total infrastructure gap: $50–80B across 2026–2030. Tier 1 alone requires $15–25B — delays cascade across the entire therapeutic development pipeline.
12-24 month deployment windows
| Infrastructure | Timeline | Market Impact |
|---|---|---|
Viral Vector Manufacturing | 18 mo | AAV production for 80% of gene therapies. Lentiviral for CAR-T. Current capacity ~1,000 litres/year; need 10,000+. Highest ROI, clearest demand, multiple customers pre-committed. |
mRNA / LNP Production Facilities | 18-24 mo | 5–7 additional GMP lipid synthesis facilities needed. Only 3–4 suppliers globally. Proven technology, 100+ therapeutics in trials. IVT platforms + fill-finish for ultra-cold products. |
Cold Chain Infrastructure | 18-24 mo | 500+ regional ultra-cold hubs needed. IoT monitoring + blockchain verification. Cryogenic transport systems. Enabling technology for ALL biologics — network effects, first-mover advantage. Enabling |
Regional Modular cGMP Facilities | 24-36 mo | Prefabricated, scalable units with 3–6 month deployment vs 18–24 month traditional builds. Cell therapy hubs within 6-hour delivery radius. Dual-use: research + clinical. |
AI Drug Discovery Compute | 24-36 mo | Molecular dynamics supercomputers, cloud-based screening, federated learning for clinical data (HIPAA/GDPR compliant). Asset-light partnership models possible. Accelerates all drug discovery. Platform |
18-36 month deployment windows
| Infrastructure | Timeline | Market Impact |
|---|---|---|
Synthetic Biology Foundries | 18-24 mo | Next-gen DNA synthesis (10x cost reduction to $0.01/bp), high-throughput screening, AI-guided design-build-test-learn cycles. 10–15 regional biofoundry hubs globally. |
Clinical Sequencing Capacity (NGS) | 24-36 mo | Whole-genome sequencing centres: 500K genomes/year today, need 10M+ by 2030. Liquid biopsy infrastructure for early cancer detection. AI pathology with 10,000+ imaging systems. |
ATMP Testing Labs & Organ-on-Chip | 24-36 mo | Only 20–30 specialised ATMP testing labs globally; need 100+. Organ-on-chip manufacturing scale-up from academic batches to GMP-compliant production. $400M → $6–8B market by 2030. |
24-60 month deployment windows
| Infrastructure | Timeline | Market Impact |
|---|---|---|
Biological Raw Materials Diversification | 36-48 mo | 80% of critical enzymes from single suppliers. Growth media, cell culture reagents, filtration membranes, chromatography resins. Synthetic alternatives to animal-derived materials. |
Digital Quality & Regulatory Systems | 30-36 mo | Blockchain-based chain of custody, AI-driven deviation detection, real-time release testing platforms. Regulatory science centres for FDA/EMA/PMDA harmonisation. |
Biotech Workforce Development | 36-60 mo | 15,000 bioprocess engineer shortage by 2030. Corporate training centres, university partnerships, apprenticeship programmes for regulatory and computational biology talent. Strategic |
TIER 1 — CRITICAL
5 priority targets
12-24 month windows
TIER 2 — HIGH PRIORITY
3 priority targets
18-36 month windows
TIER 3 — MEDIUM PRIORITY
3 priority targets
24-60 month windows
What We're Looking For
Gene therapies, CRISPR delivery, precision medicine platforms, AI drug discovery with demonstrated 2–3x success rate improvement over traditional methods.
Robust patent portfolios, clinical or pre-clinical data, clear regulatory pathway (FDA Breakthrough Therapy, Accelerated Approval). Published, peer-reviewed validation.
Large addressable markets with significant unmet needs. Platform approaches enabling multiple therapeutic applications. Modular designs supporting technology upgrades.
Proven founders in R&D, clinical trials, and commercialisation. Deep scientific expertise combined with pharmaceutical industry go-to-market capability.
Fit for pharma collaborations, licensing agreements, and CDMO anchoring. Government co-funding potential (BARDA, EU grants, NIH). Pre-committed customer base.
Clear strategy for FDA/EMA approval. Early regulatory engagement. Designs that exceed compliance requirements — flexible for evolving standards.
Geographic Focus:
Value Creation Strategy
Scientific advisory, R&D optimisation, and clinical trial navigation
Licensing, CDMO anchoring, and co-development with top-10 pharma
FDA/EMA pathway strategy, compliance, and expedited approval support
Setcoin Intelligence on therapeutic trends and competitive landscape
Expansion support into US, EU, and Asian pharmaceutical markets
Risk Management
The fund employs rigorous risk management across regulatory, technical, and geopolitical dimensions
Expert validation panels; modular design; platform approaches
Milestone-based funding; CDMO revenue bridges; diversified portfolio.
Early FDA/EMA engagement; overcompliance; flexible facility designs.
Diversified customer base; multiple indications; platform technology
Specialised capabilities; speed-to-market; cost advantage via scale.
Regional hubs; dual-sourcing; strategic stockpiling for critical enzymes.
Related Intelligence
100+ therapeutics in trials from cancer vaccines to rare diseases. The lipid nanoparticle bottleneck and why 5–7 new GMP synthesis facilities are needed immediately.
Read Analysis
Deep analysis of biomanufacturing capacity crisis, cold chain bottlenecks, and the $50–80B infrastructure investment needed across the biotech value chain.
Read Study
From -196°C cryogenic transport to IoT-enabled monitoring. Why 500+ regional hubs are needed and the first-mover advantage in cold chain infrastructure.
Read Analysis
Why AAV and lentiviral production capacity must scale 10x by 2030 and how first movers in vector manufacturing will dominate the cell therapy supply chain.
Read Thesis
Why specialised compute infrastructure for molecular dynamics represents a $3–5B investment opportunity accelerating the entire pharmaceutical pipeline.
Read Analysis
90% of drugs that pass animal testing fail in humans. How organ-on-chip and microphysiological systems will reshape preclinical development by 2030.
Read ProjectionsFrequently Asked Questions
A Luxembourg-domiciled equity fund managed by Setcoin Group that finances the manufacturing backbone of modern medicine — viral vector and mRNA/LNP production, ultra-cold logistics, AI drug discovery compute, modular cGMP facilities and diagnostics.
The global biotech market reached $2.79 trillion in 2026, but cell and gene therapy production capacity is at 15–20% of projected 2030 demand, cold chain fails 15–25% of personalised therapies and only 3–4 suppliers produce mRNA lipids. The $50–80B infrastructure gap offers 40–60% gross margins with demand visibility from every therapeutic developer.
Viral vector manufacturing (€2–4B), mRNA/LNP production facilities (€2-3B), cold chain infrastructure (€4-7B), regional modular cGMP facilities (€3-5B) and AI drug discovery compute (€2-4B) — €13-23B in total over 12-24 month windows.
Biotech infrastructure ventures, CDMO platforms and enabling technology companies with strong scientific foundations and IP, a clear FDA/EMA regulatory pathway, scalable platform approaches and pharma partnership or CDMO anchoring potential.
Qualified institutional investors only.
United States, European Union, United Kingdom, Japan, Australia, Israel and the Middle East.
How to Start
Whether you're looking to invest in the fund or submit a biotech infrastructure venture for funding consideration, we're ready to start the conversation.
